A Reversal for THROMBOGENICS NV ORDINARY SHARES BELGIU (OTCMKTS:TBGNF) Is Near. The Stock Has Decrease in Shorts

September 30, 2018 - By Robert Shackelford


The stock of THROMBOGENICS NV ORDINARY SHARES BELGIU (OTCMKTS:TBGNF) registered a decrease of 8.77% in short interest. TBGNF’s total short interest was 55,100 shares in September as published by FINRA. Its down 8.77% from 60,400 shares, reported previously. With 100 shares average volume, it will take short sellers 551 days to cover their TBGNF’s short positions.

It closed at $6.61 lastly. It is down 0.00% since September 30, 2017 and is . It has underperformed by 15.62% the S&P500.

ThromboGenics NV, an integrated biopharmaceutical company, develops and commercializes medicines that address unmet clinical needs in ophthalmology in Belgium and internationally. The company has market cap of $244.09 million. The company's lead product is JETREA used for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction. It has a 9.36 P/E ratio. It has research and development agreements with BioInvent International AB to develop Anti-PlGF, a product candidate to treat Medulloblastoma, a pediatric malignant brain tumor; Eleven Biotherapeutics and Bicycle Therapeutics to develop and commercialize products for the treatment of eye diseases with diabetics; and Chilltern International, Inc. and Outcome Sciences, Inc., as well as Parexel to provide clinical research services for the development of JETREA.

Another recent and important Oxurion NV (OTCMKTS:TBGNF) news was published by Seekingalpha.com which published an article titled: “ThromboGenics becomes Oxurion” on September 05, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: